Skip to main content

Esophageal Cancer Clinical Trials

Review the esophageal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 133

mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Status: Active
Location: 717 locations
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Status: Active
Location: 349 locations
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: 76 locations
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Status: Active
Location: 16 locations
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Status: Active
Location: 13 locations
Pembrolizumab with Trastuzumab and Chemotherapy for the Treatment Resectable HER2-Positive Gastric, Esophageal, and Gastroesophageal Junction Cancer
Status: Active
Location: 10 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 10 locations
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Status: Active
Location: 8 locations
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Status: Active
Location: 9 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 9 locations
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Status: Active
Location: 7 locations
FLOT and Chemoradiation before Surgery for the Treatment of Resectable Esophageal or Gastroesophageal Junction Cancer
Status: Active
Location: 7 locations
Combination Chemotherapy for the Treatment of Metastatic or Unresectable Gastroesophageal Cancers, SAGE Trial
Status: Active
Location: 7 locations
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Status: Active
Location: 7 locations
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 7 locations
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
Status: Active
Location: 11 locations
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Status: Active
Location: 7 locations
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Status: Active
Location: 7 locations
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Status: Active
Location: 5 locations
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Status: Active
Location: 7 locations
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 5 locations
Avatrombopag for the Treatment of Persistent Chemotherapy-Induced Thrombocytopenia in Patients with Gastrointestinal Malignancies
Status: Active
Location: 4 locations
Fluorouracil, Oxaliplatin, and Liposomal Irinotecan with or without Trastuzumab, Nivolumab, and Pembrolizumab for the First Line Treatment of Advanced Esophageal or Gastric Adenocarcinoma
Status: Active
Location: 4 locations